Cagrilinitide Pharmacokinetics: Absorption, Distribution, Half-Life, and Metabolism

Overview

Cagrilinitide (internal code AM833; Novo Nordisk) is a long-acting, acylated amylin analog designed to overcome the key pharmacokinetic liabilities of native human amylin and its first-generation clinical analog pramlintide. Native amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. It reduces postprandial glucagon, slows gastric emptying, and activates satiety circuits in the hypothalamus and area postrema. Despite those mechanisms, native amylin is nearly unusable as a drug: it aggregates rapidly into amyloid fibrils, and its plasma half-life is only a few minutes.

Pramlintide (FDA-approved as Symlin in 2005) replaced three key residues to prevent aggregation but left the half-life problem unsolved; it requires subcutaneous injection three times daily. Cagrilinitide addresses both problems through structural re-engineering and fatty acid conjugation, yielding a molecule capable of once-weekly subcutaneous dosing.

Understanding cagrilinitide’s pharmacokinetic (PK) profile is important for interpreting the clinical data, particularly the Phase II CagriSema combination studies (cagrilinitide + semaglutide 2.4 mg) that have generated considerable attention in the obesity pharmacology literature. This reference page covers absorption, distribution, half-life, metabolic clearance, and the structural basis for each PK parameter.

Key primary references used throughout this page:

• Chung CW et al. “Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.” J Obes Metab Syndr. 2026;35(1). PMID 41549439.
• Volcanek S et al. “Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.” Diabetes Ther. 2025 Jun. PMID 40332747.
• Ismaiel A et al. “Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity.” Int J Obes (Lond). 2025 Oct. PMID 40804463.

Molecular design and structural basis for improved PK

Cagrilinitide is built on a modified human amylin backbone with two layers of engineering that directly determine its pharmacokinetic behavior.

1. Aggregation-prevention substitutions. Native amylin contains a segment (residues 20-29) highly prone to forming beta-sheet amyloid fibrils, which is what makes raw amylin unusable clinically. Cagrilinitide incorporates proline substitutions at key positions within this segment, breaking the hydrogen-bonding geometry that drives aggregation. This is the same strategy pramlintide uses (Pro25, Pro28, Pro29), but cagrilinitide’s specific substitution pattern is optimized for both aggregation resistance and receptor affinity at the amylin receptor subtypes (AMY1, AMY2, AMY3).

2. C20 fatty acid conjugation via a linker. The defining PK innovation is attachment of a C20 fatty diacid moiety through a flexible hydrophilic linker at a lysine residue on the peptide backbone. This is structurally analogous to the fatty acid chemistry used in semaglutide (GLP-1 receptor agonist) and insulin degludec. In plasma, the fatty acid tail binds non-covalently and reversibly to serum albumin (human serum albumin, molecular weight ~66 kDa). Albumin binding achieves three things simultaneously:

• It dramatically slows renal glomerular filtration (albumin is too large to filter freely, and the bound peptide is carried with it).
• It creates a depot effect in plasma, releasing free cagrilinitide slowly over days.
• It protects the peptide backbone from rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other circulating proteases.

The net result of these two engineering layers is a molecule that retains full amylin receptor agonist activity while exhibiting a terminal half-life approximately 200-fold longer than pramlintide.

flowchart TD
    A[Subcutaneous injection depot] -->|slow absorption via lymphatics| B[Systemic circulation]
    B --> C{Albumin binding equilibrium}
    C -->|bound fraction ~98-99%| D[Albumin-cagrilinitide complex]
    C -->|free fraction ~1-2%| E[Active free cagrilinitide]
    D <-->|slow reversible release| E
    E -->|binds| F[Amylin receptors AMY1 / AMY2 / AMY3]
    E -->|minor proteolysis| G[Peptide fragments - inactive]
    D -->|prevents| H[Renal glomerular filtration]
    F --> I[Satiety signaling: hypothalamus + area postrema]
    F --> J[Slowed gastric emptying]
    F --> K[Suppressed postprandial glucagon]

The linker chemistry is also critical for subcutaneous depot formation. Following injection, cagrilinitide forms a loose, non-amyloid association at the injection site that further delays entry into the lymphatic and vascular compartments.

Absorption: subcutaneous route and Tmax

Cagrilinitide is administered exclusively by subcutaneous (SC) injection. No intravenous or oral formulation has advanced to clinical evaluation as of early 2026. The SC route for acylated peptides of this class follows a well-characterized absorption pattern.

Depot formation and rate-limiting step. Following SC injection into the abdomen or thigh, cagrilinitide distributes into the interstitial space. The rate-limiting step in absorption is not dissolution (the drug is in solution) but lymphatic uptake and transcapillary movement out of the interstitial compartment. The fatty acid-albumin interaction begins partly at the injection site as endogenous albumin infiltrates the depot, further prolonging the absorption phase.

Tmax. In Phase I and Phase II clinical pharmacology data reported by Novo Nordisk, peak plasma concentrations (Tmax) for cagrilinitide are observed approximately 24 to 72 hours after a single SC dose. This broad Tmax window is typical for fatty-acid-conjugated peptides; compare semaglutide (Tmax ~1-3 days SC) and insulin degludec (Tmax ~9 hours SC). The extended Tmax means that cagrilinitide does not produce sharp peak-to-trough plasma swings, which is pharmacologically relevant because rapid concentration spikes can drive nausea with amylin-class compounds.

Bioavailability. Absolute SC bioavailability for cagrilinitide has not been published in a peer-reviewed paper as of this writing. For analogously engineered fatty acid peptides, SC absolute bioavailability typically ranges from 70% to 90% (semaglutide: ~89% SC; insulin degludec: ~91% SC). Cagrilinitide is expected to fall in a similar range based on its structural class, though confirmatory bioavailability data from published Phase I studies are awaited.

Site of injection. Clinical trial protocols for the Phase II CAGRISEMA study (NCT04982575) used the abdomen as the primary injection site, consistent with standard SC peptide administration. Regional variation in absorption (abdomen vs. thigh vs. upper arm) has not been specifically characterized for cagrilinitide in published data; the same site-consistency guidance applied to semaglutide and insulin analogs is generally assumed to apply.

Practical note for trial protocols. Because absorption is slow and Tmax is delayed 1-3 days, steady-state plasma concentrations are only reached after approximately 4-5 half-lives of once-weekly dosing. At a ~7-day half-life, this means approximately 4-5 weeks of weekly dosing before steady-state plasma exposure is achieved. This explains the stepwise dose-escalation schedules used in CagriSema trials.

Distribution: volume of distribution and albumin binding

Volume of distribution (Vd). Cagrilinitide’s volume of distribution is expected to be relatively low and confined close to plasma and well-perfused tissues, consistent with its high albumin binding. Highly albumin-bound drugs typically show Vd values in the range of 0.07 to 0.15 L/kg (roughly plasma volume plus some extravascular distribution), because albumin itself does not freely cross most tissue barriers and the drug is sequestered on albumin. For comparison, semaglutide has a Vd of approximately 12.5 liters in humans, consistent with near-total plasma binding. Published Vd values for cagrilinitide specifically have not been reported in peer-reviewed literature as of 2026; regulatory submission dossiers (EMA, FDA) will contain these data when and if the compound reaches marketing authorization.

Albumin binding fraction. Based on the fatty acid length (C20) and linker design, cagrilinitide is expected to bind serum albumin at the same fatty acid binding sites (Sudlow site II and the FA6-FA7 region) used by long-chain fatty acids and acylated insulin analogs. The bound fraction is likely in the range of 97-99%, with 1-3% circulating as pharmacologically active free peptide. This free fraction is in rapid equilibrium with the albumin-bound fraction, so tissue receptor exposure tracks total plasma concentration on a proportional basis.

CNS penetration. Amylin receptor agonists exert their satiety effects primarily at circumventricular organs (the area postrema, subfornical organ) and the hypothalamic arcuate nucleus. Critically, the area postrema and subfornical organ lie outside the blood-brain barrier (BBB), allowing peripheral peptides to access amylin receptors in these regions without needing to penetrate the BBB. Cagrilinitide does not need to cross the BBB to produce its primary pharmacological effects. This is a key architectural advantage over CNS-penetrant weight-loss drugs and explains why amylin receptor agonists as a class show a favorable central nervous system safety profile.

Protein binding interactions. Competitive displacement of cagrilinitide from albumin by other highly albumin-bound drugs (e.g., warfarin, NSAIDs, sulfonamides) is a theoretical concern common to all fatty-acid-conjugated peptides. In practice, semaglutide shows no clinically meaningful drug-drug interactions mediated via albumin displacement, and the same is expected for cagrilinitide, but formal interaction studies have not been published in the open literature.

Half-life and elimination

Terminal half-life. The most clinically significant PK parameter for cagrilinitide is its terminal elimination half-life (t1/2) of approximately 7 days (roughly 160-170 hours). This figure is inferred from the once-weekly dosing regimen used in Phase I/II clinical pharmacology studies and the accumulation ratio reported by Novo Nordisk. A ~7-day t1/2 with once-weekly dosing produces a peak-to-trough plasma ratio well under 2-fold at steady state, meaning plasma exposure is substantially flat across the dosing interval.

For context, the half-life progression across the amylin class is stark:

Mechanism of prolonged half-life. Three factors combine to produce the ~7-day t1/2:

1. Albumin shielding from proteolytic enzymes (DPP-IV, neprilysin, other endopeptidases).
2. Reduction in renal clearance: the albumin-peptide complex is too large for glomerular filtration; only the free fraction is filterable.
3. The equilibrium dissociation constant (Kd) of the fatty acid-albumin interaction is in the low micromolar range, providing sustained, controlled release of active drug over days rather than minutes or hours.

Elimination route. Cagrilinitide, like all peptide therapeutics, is ultimately broken down into amino acids by proteolytic enzymes and excreted as small peptide fragments and amino acids via renal and biliary routes. The fatty acid side chain undergoes beta-oxidation similar to endogenous long-chain fatty acids. No unchanged cagrilinitide is expected to be recovered in urine or feces, consistent with the elimination pattern of semaglutide and insulin degludec. Formal mass-balance studies in humans have not been published in peer-reviewed literature.

Renal impairment. Because renal filtration of the intact peptide is already minimal (due to albumin binding), moderate renal impairment is not expected to meaningfully alter cagrilinitide PK. This is analogous to semaglutide, where renal dose adjustment is not required across impairment stages. Cagrilinitide-specific renal impairment data from clinical pharmacology substudies are anticipated in regulatory filings but are not yet published.

Hepatic impairment. Hepatic metabolism plays a limited role for acylated peptides of this class. Formal hepatic impairment studies for cagrilinitide are pending.

Metabolism and clearance mechanisms

Cagrilinitide is a peptide and, like all peptides administered systemically, is subject to proteolytic rather than cytochrome P450 (CYP)-mediated metabolism. This has important practical consequences: cagrilinitide is not expected to be a CYP substrate, inhibitor, or inducer, and the risk of conventional small-molecule drug-drug interactions via hepatic metabolic pathways is essentially nil.

Proteolytic degradation. Once dissociated from albumin, the free cagrilinitide peptide is susceptible to several classes of circulating and tissue-associated proteases:

• Dipeptidyl peptidase IV (DPP-IV): DPP-IV cleaves dipeptides from the N-terminus of proline- or alanine-containing peptides. Cagrilinitide’s N-terminal residues and the proline substitutions in the aggregation-prone region may confer partial resistance to DPP-IV, though this has not been directly confirmed in published biochemical studies.
• Neutral endopeptidase (neprilysin, NEP/CD10): Neprilysin cleaves on the N-terminal side of hydrophobic residues. Native amylin is a known neprilysin substrate; cagrilinitide’s modified backbone is expected to reduce (but not eliminate) neprilysin susceptibility.
• Non-specific endopeptidases: Tissue-associated endopeptidases contribute to peptide clearance in the kidney, liver, and intestinal wall, though albumin shielding significantly reduces access for the majority of the dosing interval.

Fatty acid side chain metabolism. The C20 fatty diacid linker, once released from the peptide backbone by proteases, follows the same metabolic pathway as dietary and endogenous long-chain fatty acids: beta-oxidation in liver mitochondria and peroxisomes, generating acetyl-CoA. No accumulation of the fatty acid linker is expected.

Drug-drug interaction profile. No CYP-mediated interactions are anticipated. Albumin-displacement interactions are theoretically possible (see Distribution section) but have not been observed clinically in the broader class. No formal published DDI studies for cagrilinitide are available as of April 2026.

Immunogenicity considerations. Like all peptide drugs, cagrilinitide carries some risk of anti-drug antibody (ADA) formation. Phase II CAGRISEMA data did not report clinically meaningful immunogenicity signals, and the modified backbone is intended to reduce immunogenic potential relative to native amylin. ADA presence can theoretically alter PK by accelerating clearance or, in rare cases, extending half-life via immune complex formation; monitoring for ADAs is standard in the ongoing clinical program.

A 2026 review of amylin analogs in diabesity (PMID 41549439) underscored that the PK improvements in long-acting analogs are the primary reason for renewed clinical interest in the amylin pathway after years of limited progress following pramlintide’s 2005 approval.

Pharmacokinetic-pharmacodynamic (PK-PD) relationships

Understanding cagrilinitide’s PK is only half the picture; the other half is how plasma exposure translates into pharmacological effect at amylin receptors.

Receptor targets. Cagrilinitide acts at amylin receptor complexes: heterodimers of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), forming AMY1, AMY2, and AMY3 respectively. These receptors are expressed at high density in the area postrema and hypothalamic arcuate nucleus, the two primary satiety-regulating brain regions accessible to peripherally administered peptides via circumventricular gaps in the blood-brain barrier.

Sustained occupancy drives durable satiety. Because cagrilinitide’s free plasma fraction remains approximately constant across the 7-day dosing interval (trough is only modestly lower than peak at steady state), receptor occupancy in the hypothalamus and area postrema is sustained throughout the week. This is a mechanistic advantage over pramlintide, where three-times-daily dosing still produces interprandial troughs with negligible amylin receptor activity. A 2025 review (Volcanek S et al., PMID 40332747) summarized evidence that continuous amylin receptor stimulation produces additive effects on satiety, gastric emptying, and glucagon suppression compared to pulsatile exposure.

Combination PK-PD with semaglutide (CagriSema). In the CAGRISEMA Phase II trial (NCT04982575), cagrilinitide was co-administered with semaglutide 2.4 mg SC weekly. Both agents are once-weekly SC injections, and their PK profiles are well-matched. Semaglutide’s t1/2 is approximately 7 days, making the two compounds nearly pharmacokinetically synchronized. No PK interaction between cagrilinitide and semaglutide has been reported; they bind different albumin sites and act on entirely different receptors (GLP-1R for semaglutide; CTR/RAMP for cagrilinitide). The weight-loss effect in the combination arm (~15.6% body weight at 32 weeks, 2.4 mg/2.4 mg dose) exceeded either monotherapy arm, consistent with complementary rather than redundant mechanisms.

Dose-response. The Phase II CAGRISEMA data reported dose-dependent weight loss for cagrilinitide across 0.3 mg, 0.6 mg, 1.2 mg, and 2.4 mg weekly doses. This dose-response relationship supports a classic Emax PK-PD model where the fraction of amylin receptors occupied scales with free plasma cagrilinitide concentration, and weight loss effect scales with receptor occupancy. Formal PK-PD modeling results (EC50 estimates, Emax parameters) have not been published in peer-reviewed literature but are expected in regulatory submissions.

Gastric emptying delay. One important PD consequence of sustained amylin receptor activation is prolonged slowing of gastric emptying. Because this effect is present throughout the week (not just postprandially, as with pramlintide), patients receiving cagrilinitide may experience more persistent early satiety and, in higher doses, nausea and vomiting. This underscores the importance of dose escalation schedules that allow PD adaptation as plasma concentrations build toward steady state.

Comparison with pramlintide and other amylin analogs

Cagrilinitide exists within a landscape of amylin-pathway compounds at various stages of development. The table below compares key PK parameters across the clinically relevant analogs.

Davalintide (AC2307) was a second-generation amylin analog developed by Amylin Pharmaceuticals. It improved aggregation resistance versus pramlintide but lacked fatty acid conjugation, leaving the half-life in the range of 2-4 hours. Despite showing efficacy in early Phase II studies, the dosing burden (daily SC injection) and the competitive landscape led to program discontinuation. Cagrilinitide solved the half-life problem that davalintide left unaddressed.

KBP-336 (KeyBiologics, in early development) and similar investigational amylin/calcitonin receptor agonists are pursuing oral and intranasal delivery routes, which would introduce entirely different absorption PK profiles. None have reached Phase II as of 2026.

Clinical significance of the PK gap. The 2026 review by Chung CW et al. (PMID 41549439) explicitly attributes the renaissance of the amylin pathway in obesity pharmacology to the fatty acid conjugation technology that enables once-weekly administration. The authors note that patient adherence to injectable metabolic therapies drops substantially when injection frequency exceeds once weekly, citing real-world adherence data from insulin and GLP-1 RA programs. Cagrilinitide’s PK profile thus has a direct line to clinical trial retention and real-world effectiveness that goes beyond pharmacological potency alone.

Special populations and PK considerations

Body weight and volume of distribution. For highly albumin-bound compounds with low intrinsic Vd, body weight is not expected to substantially alter total exposure on a per-kilogram basis. Semaglutide, the most comparable approved agent, shows only modest variation in AUC across body weight ranges, and no weight-based dose adjustment is required. The same is anticipated for cagrilinitide, though formal population PK analyses across body mass index categories have not been published.

Sex differences. No clinically meaningful sex difference in PK has been identified for semaglutide. Cagrilinitide-specific sex-stratified PK data are not yet published. The CAGRISEMA Phase II trial enrolled participants with obesity of both sexes; any sex-stratified PK substudy findings will appear in regulatory submission packages.

Age. Albumin concentrations decline modestly in older adults (serum albumin below 3.5 g/dL is common in hospitalized elderly populations). A meaningful drop in albumin binding could in principle increase the free fraction of cagrilinitide and alter its effective exposure and clearance. However, in outpatient settings with typical albumin levels (3.5-5.0 g/dL), age-related variation in albumin is not expected to produce clinically significant PK differences. Formal elderly population PK data are not yet published.

Hepatic impairment. Because cagrilinitide is not metabolized by CYP enzymes and relies on proteolytic degradation, moderate hepatic impairment is not expected to markedly affect cagrilinitide PK. Severe hepatic impairment can reduce albumin synthesis, which might in principle increase free fraction, but formal studies are pending.

Renal impairment. As detailed in the Elimination section, the albumin-bound peptide is not subject to significant glomerular filtration. Mild to moderate renal impairment is unlikely to require dose adjustment. Severe renal impairment and end-stage renal disease scenarios are under evaluation.

Pregnancy and lactation. No human PK or safety data exist for cagrilinitide in pregnancy or lactation. This is a standard research-phase compound caveat; cagrilinitide is not approved for any indication.

Drug interactions (pharmacokinetic). No CYP-mediated DDIs are anticipated. The most plausible DDI pathway is competitive albumin displacement by drugs with high albumin affinity (warfarin Kd ~20-40 nM; ibuprofen Kd ~1-10 microM; furosemide Kd ~100 nM). These interactions are expected to be minor, consistent with the semaglutide DDI profile, but have not been formally studied for cagrilinitide.

Open questions and what to watch for in Phase III data

Several PK questions remain unanswered in the published literature as of April 2026. Researchers and clinicians following the cagrilinitide clinical program should watch for the following in upcoming Phase III trial publications, regulatory filings, and conference presentations:

1. Formal absolute bioavailability study. A dedicated bioavailability study comparing SC to IV administration will establish the SC bioavailability fraction precisely. This is typically required by both FDA and EMA as part of the NDA/MAA package.

2. Mass-balance and excretion route characterization. A radiolabeled ([14C]) mass-balance study will define exactly how much cagrilinitide and its metabolites are excreted via urine vs. feces vs. exhaled CO2 (for the fatty acid component). This is standard for NDA filing.

3. Injection-site PK variability. Head-to-head PK comparisons of abdomen vs. thigh vs. upper arm injection sites will quantify intra- and inter-subject variability in absorption rate, which matters for clinical label guidance.

4. PK in adolescents. Given the potential for cagrilinitide to eventually be evaluated in adolescent obesity (a growing regulatory priority following tirzepatide and semaglutide pediatric filings), pediatric PK studies are anticipated.

5. Long-term steady-state PK and potential PK tolerance. Whether chronic amylin receptor stimulation leads to receptor downregulation that could alter effective PK-PD coupling over months to years is unknown. The ongoing Phase III REDEFINE and OASIS/FLOW-extension programs will provide exposure-response data over longer timeframes than the 32-week Phase II window.

6. Population PK model. A population PK (PopPK) analysis using pooled Phase II and Phase III data will quantify the contribution of age, sex, body weight, renal function, and hepatic function to interindividual PK variability. This model will underpin any label guidance for special populations.

These open questions are not red flags; they reflect the standard lifecycle of a compound moving from Phase II to regulatory submission. The Phase II data already demonstrate that cagrilinitide’s PK profile is fit for purpose as a once-weekly injectable, and the combination with semaglutide is pharmacokinetically sound. The unanswered questions are matters of characterization depth, not fundamental viability.

Summary

Cagrilinitide’s pharmacokinetic profile represents a qualitative improvement over all prior amylin-pathway compounds and is the primary reason this class of therapeutics has re-entered serious clinical development after years of dormancy following pramlintide.

The key PK facts in brief:

• Route: Subcutaneous injection only (no oral or IV formulation in clinical evaluation as of 2026).
• Absorption: Slow, depot-mediated; Tmax approximately 24-72 hours post-dose.
• Distribution: High albumin binding (~97-99% bound); low volume of distribution confined near plasma; no BBB penetration required for primary mechanism (area postrema and circumventricular organ access is sufficient).
• Half-life: Approximately 160-170 hours (7 days), driven by C20 fatty acid-albumin binding.
• Metabolism: Proteolytic (not CYP-mediated); no conventional DDIs expected.
• Elimination: Amino acid catabolism and beta-oxidation of fatty acid side chain; minimal renal clearance of intact peptide.
• Special populations: No dose adjustment anticipated for moderate renal or hepatic impairment; formal data pending.
• PK-PD: Sustained receptor occupancy across the once-weekly dosing interval supports durable satiety signaling. Well-matched PK with semaglutide supports the CagriSema combination rationale.

For researchers and clinicians interpreting cagrilinitide clinical trial data: the ~7-day half-life means that steady-state plasma exposure is not reached until weeks 4-5 of weekly dosing. Dose-escalation schedules in clinical protocols are designed around this accumulation kinetics, and efficacy endpoints measured before steady state should be interpreted accordingly.

Regulatory status (April 2026): Cagrilinitide is an investigational compound. It is not approved by the FDA, EMA, or any other regulatory authority for any indication. All PK and clinical information on this page is drawn from published peer-reviewed literature (PMIDs 41549439, 40332747, 40804463) and publicly available clinical trial disclosures (ClinicalTrials.gov: NCT04982575). This page is intended for research and educational purposes only and does not constitute medical advice.

See also

More on Cagrilinitide:

• Cagrilinitide research overview
• Cagrilinitide: Mechanism of action
• Cagrilinitide: Clinical & preclinical evidence
• Cagrilinitide: Safety profile
• Cagrilinitide: Dose-response

Head-to-head comparisons:

• Semaglutide vs Cagrilinitide